Joan Shen ends the year by saying goodbye to I-Mab; CRISPR Therapeutics puts coal in R&D chief’s stocking

Deck the halls with more appointments in the last Peer Review for 2021. Thanks for reading every week!

Joan Shen

→ When the calendar flips to 2022, Joan Shen is out at I-Mab “to pursue other interests,” leaving founder and chairman Jingwu Zang

Click to view original post